Overview

A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Centocor, Inc.
Collaborator:
Centocor BV
Treatments:
Golimumab